The Drug Enforcement Administration classified the drug methylenedioxymeth-amphetamine, MDMA, also known as Ecstacy, as a Schedule I controlled substance on July 1, 1985. The controversy surrounding the classification of MDMA is related to the question of its efficacy as an adjunct to psychotherapy and the larger issue of how to regulate the production and use of designer drugs. The authors review the literature on MDMA and its predecessor, MDA, a substance that differs from MDMA by one methyl group.
Get full access to this article
View all access options for this article.
References
1.
LawnJ. C., Federal Register, 50, pp. 23118–23120, 1985.
2.
MullenF. M., Federal Register, 49, pp. 50732–50733, 1984.
3.
BaumR. M., New Variety of Street Drugs Poses Growing Problems, Chemical and Education News, pp. 7–16, September 9, 1985.
4.
Drug Control Section, Office of Diversion Control; “Schedule I Control Recommendation Under the CSA for MDMA,” January, 1984, papers gathered by Rick Doblin, August 8, 1984.
5.
SmithD. E. and SeymourR., MDA, AKA The Love Drug, Psychedelic Speed, High Times, p. 30, April 30, 1985.
6.
LomanJ.MyersonP. G., and MyersonA., Experimental Pharmacology of Postencephalitic Parkins's Disease, Transactions of the American Neurological Association, 67, pp. 201–203, 1941.
7.
BrownH. D., MDA as an Antitussive, U.S. Patent 2,820,739, 1958.
8.
Smith, Kline, and French Laboratories, MDA as an Ataractic, British patent 82880, 1960.
9.
CookL. and FellowsJ., MDA as Anorexigenic, U.S. Patent 2,984,148, 1961.
10.
VaupelD. M.NozakiM.MartinW., The Inhibition of Food Intake in the Dog by LSD, Mescaline, Psilocybin, d-Amphetamine and Phenylisopropylamine Derivatives, Life Sciences, 24, pp. 2427–2432, 1979.
11.
MackR. B., MDA—Another Stupefacente, North Carolina Medical Journal, 43, pp. 777–778, 1982.
12.
FrankR. S., The Clandestine Drug Laboratory Situation in the United States, Journal of Forensic Science, 28, pp. 18–31, 1983.
13.
PoklisA.MacKellM. A., and DrakeW. K., Fatal Intoxication from 3,4-Methylenedioxyamphetamine, Journal of Forensic Science, 24, pp. 70–75, 1979.
14.
LukaszewskiT., 3,4-Methylenedioxyamphetamine Overdose, Clinical Toxicology, 15, pp. 405–409, 1979.
15.
CimburaG., 3,4-Methylenedioxyamphetamine (MDA): Analytical and Forensic Aspects of Fatal Poisoning, Journal of Forensic Science, 17, pp. 329–333, 1972.
16.
ReedD.CraveyR. H., and SedgwickP. R., A Fatal Case Involving Methylenedioxyamphetamine, Clinical Toxicology, 5, pp. 3–6, 1972.
17.
SimpsonD. L. and RumackB. H., Methylenedioxyamphetamine: Clinical Description of Overdose, Death, and Review of Clinical Pharmacology, Archives of Internal Medicine, 141, pp. 1507–1509, 1981.
18.
MeyersF. H.RoseA., and SmithD. E., Incidents Involving the Haight-Ashbury Population and Some Uncommonly Used Drugs, Journal of Psychedelic Drugs, 1, pp. 139–146, 1967–1968.
19.
RichardsK. C. and BorgstedtH. H., Nonfatal Reaction to the Ingestion of the Hallucinogenic Drug MDA, Journal of the American Medical Association, 218, pp. 1826–1827, 1971.
20.
RichardsR. N., Experience with MDA, Canadian Medical Association Journal, 106, pp. 256–259, 1972.
21.
CimburaG., PMA Deaths in Ontario, Canadian Medical Association Journal, 110, pp. 1263–1265, 1974.
22.
PatonD. M.BellJ. I.YeeR., Pharmacology and Toxicity of 3,4-Methylenedioxyamphetamine, Paramethoxyamphetamine, and Related Dimethoxyamphetamines, Proceedings of the Western Pharmacological Society, 18, pp. 229–231, 1975.
23.
LoptakaJ. E.BrewertonC. N.BrooksD. S., The Protective Effects of Methysergide, 6-Hydroxydopamine, and Other Agents on the Toxicity of Amphetamine, Phentermine, MDA, PMA, and STP in Mice, Research Communications in Chemical Pathology and Pharmacology, 14, pp. 611–696, 1976.
24.
ThiessenP. N. and CookD. A., The Properties of 3,4-Methylenedioxyamphetamine (MDA) II. Studies of Acute Toxicity in the Mouse and Protection by Various Agents, Clinical Toxicology, 6, pp. 193–199, 1973.
25.
NicholsD. E.IlhanM., and LongJ. R., Comparison of Cardiovascular, Hyperthermic, and Toxic Effects of Paramethoxyamphetamine (PMA) and 3,4-Methylenedioxyamphetamine (MDA), Archives of Internal Pharmacodynamics, 214, pp. 133–140, 1975.
26.
MarquardtG. M.DiStefanoV., and LingL., Metabolism of B-3,4-Methylenedioxyamphetamine in the Rat, Biochemical Pharmacology, 27, pp. 1503–1505, 1978.
27.
YeeR. and BellJ. I., The Pharmacology and Toxicity of 3,4-Methylenedioxyamphetamine (MDA) and PMA, Texas Report on Biological Medicine, 33, p. 610, 1975.
28.
BenningtonF.MorinR. D.ClarkL. C., Psychopharmacological Activity of Ring and Sidechain Substituted B-Phenylethylamines, Journal of Organic Chemistry, 23, pp. 1979–1984, 1958.
EllisonG.EisonM. S.HubermanH. S., Long Term Changes in Dopaminergic Innervation of Caudate Nucleus After Continuous Amphetamine Administration, Science, 201, pp. 276–278, 1978.
31.
DavisW. M.WatersI. W.HatoumH. T., Triphasic Doselethality Relationships for Amphetamine and Certain Ring Substituted Amphetamines in Isolated or Aggregated Mice, Research Communications in Chemical Pathology and Pharmacology, 17, pp. 575–582, 1977.
32.
JamesR. C. and FranklinM. R., Hepatic Influences on the Triphasic Lethal Dose Curve of Amphetamine, The Pharmacologist, 18, pp. 710, 1976.
33.
BasuP.KramerP. F., and FellerD. R., Correlation of (+) Amphetamine Lethality and Hepatic Metabolism, Journal of Pharmacy and Pharmacology, 26, pp. 910–911, 1974.
34.
ShulginA. T. and JacobP., 1-(3,4-Methylenedioxyphenol)-3-aminobutane: A Potential Toxicological Problem, Journal of Toxicology and Clinical Toxicology, 19, pp. 109–110, 1982.
35.
DavisW. M. and BorneR. F., Pharmacologic Investigation of Compounds Related to 3,4-Methylenedioxyamphetamine (MDA), Substance and Alcohol Actions/Misuse, 5, pp. 105–110, 1984.
36.
JacksonB. and ReedA., Another Abuseable Amphetamine, Journal of the American Medical Association, 211, p. 830, 1970.
37.
MarquardtG. M.DiStefanoV., and LingL. L., Effects of Racemic, S(+), and R(–) Methylenedioxyamphetamine on Synaptosomal Uptake and Release of Tritiated Norepinephrine, Biochemical Pharmacology, 22, pp. 1497–1501, 1978.
38.
MarquardtG. M.DiStefanoV., and LingL. L., Pharmacological and Toxicological Effects of B-3,4-Methylenedioxyamphetamine Isomers, Toxicology and Applied Pharmacology, 45, pp. 675–683, 1978.
39.
PatonD. M., Effect of Amphetamine, 3,4-MDA, p-Methoxyamphetamine and Related Amphetamines on Uptake of Metaraminol and Efflux of Noradrenaline in Adrenergic Nervices of Rabbit Atria, Journal of Pharmacy and Pharmacology, 27, pp. 361–362, 1975.
40.
ChengH. C.LongJ. P.NicholsD. E., Effects of Psychotomimetics on Vascular Strips, Journal of Pharmacology and Experimental Therapy, 168, pp. 114–123, 1974.
41.
GlennonR. A. and YoungR., MDA: A Psychoactive Agent with Dual Stimulus Effects, Life Sciences, 34, pp. 379–383, 1984.
42.
SchweitzerJ. W.SchwartzR., and FriedhoffA. J., In Vivo Formation of Dopamine from 3,4-Methylenedioxyphenylethylamine in the Rat, Archives of Internal Pharmacodynamics, 231, pp. 21–29, 1978.
43.
GlennonR. A.LiebowitzS. M., and Leming-DootD., Demethyl Analogues of Psychoactive Methoxyphenalkylamines: Synthesis and Serotonin Receptor Affinities, Journal of Medical Chemistry, 23, pp. 990–994, 1980.
44.
GlennonR. A.LiebowitzS. M., and AndersonG. M., Serotonin Receptor Affinities of Psychoactive Phenalkylamine Analogues, Journal of Medical Chemistry, 23, pp. 294–299, 1980.
45.
NicholsD. E.LloydD. H.HoffmanA. J., Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of (3H) Serotonin from Rat Brain Synaptosomes, Journal of Medical Chemistry, 25, pp. 530–535, 1982.
46.
FairchildM. D.AilesG. A.JendenD. J., The Effects of Mescaline, Amphetamine, and Four-Ring Substituted Amphetamine Derivatives on Spontaneous Brain Electrical Activity in the Cat, International Journal of Neuropharmacology, 6, pp. 151–157, 1967.
47.
GlennonR. A. and YoungR., MDA: An Agent that Produces Stimulus Effects Similar to Those of 3,4-DMA, LSD and Cocaine, European Journal of Pharmacology, 99, pp. 249–250, 1984.
48.
FellowsE. J. and BernheimF., The Effect of a Number of Aralkylamines on the Oxidation of Tyramine by Amine Oxidase, Journal of Pharmacology and Experimental Therapeutics, 100, pp. 94–99, 1950.
49.
GlennonR. A.YoungR.RosecransJ. A., Discriminative Stimulus Properties of MDA Analogs, Biological Psychiatry, 17, pp. 807–814, 1982.
50.
AndersonG. M.BraunG.BraunV., Absolute Configuration and Psychotomimetic Activity, in NIDA Research Monograph, 22, BarnettG.TrsicM., and WilletteR. (eds.), pp. 8–15, 1978.
51.
SilvermanP. B. and HoB. T., The Discriminative Stimulus Properties of 2,5-Dimethoxy-4-methylamphetamine (DOM), Psychopharmacology, 68, pp. 209–215, 1980.
52.
GlennonR. A. and YoungR., Further Investigation of the Discriminative Stimulus Properties of MDA, Pharmacology, Biochemistry, and Behavior, 20, pp. 501–505, 1984.
53.
GlennonR. A.YoungR., and RosecransJ. A., Antagonism of the Effects of the Hallucinogen DOM and the Purported 5-HT Agonist Quipazine by 5-HT2 Antagonists, European Journal of Pharmacology, 91, pp. 189–196, 1983.
54.
ShannonH. E., MDA and DOM, Psychopharmacology, 67, pp. 311–312, 1980.
55.
GriffithsR. R.WingerG.BradyJ. V., Comparisons of Behavior Maintained by Infusions of Eight Phenylethylamines in Baboons, Psychopharmacology, 50, pp. 251–258, 1976.
56.
ShawM. A. and PeelH. W., Thin Layer Chromatography of 3,4-Methylenedioxyamphetamine, 3,4-Methylenedioxymethamphetamine and Other Phenethylamine Derivatives, Journal of Chromatography, 104, pp. 201–204, 1975.
57.
LebishP.FinkleB. S., and BrackettJ. W., Determination of Amphetamine, Methamphetamine, and Related Amines in Blood and Urine by Gas Chromatography with Hydrogen Flame-Ionization, Clinical Chemistry, 16, pp. 195–200, 1970.
58.
MidhaK. K., Identification of Two In Vitro Metabolites of 3,4-Methylenedioxyamphetamine by Gas-Liquid Chromatograph-Mass Spectrometry, Journal of Chromatography, 101, pp. 210–214, 1974.
59.
DeMayoM. M.BrigliaE. J., and DalCortivoL. A., Colorometric Determination of 3,4-Methylenedioxyamphetamine (MDA), Journal of Forensic Science, 17, pp. 444–446, 1972.
60.
NaranjoC.ShulginA. T., and SargentT., Evaluation of 3,4-Methylenedioxyamphetamine (MDA) as an Adjunct to Psychotherapy, Medical Pharmacological Experiments, 17, pp. 359–364, 1967.
61.
TurekI. S.SoskinR. A., and KurlandA. A., Methylenedioxyamphetamine (MDA) Subjective Effects, Journal of Psychedelic Drugs, 6, pp. 7–14, 1974.
62.
DiLeoF. B., Psychotherapy with Psychedelic Drugs, Journal of Psychoactive Drugs, 13, pp. 319–323, 1981.
63.
YensenR.DiLeoF.RheadJ. C., MDA-Assisted Psychotherapy with Neurotic Outpatients: A Pilot Study, Journal of New Mental Diseases, 63, pp. 233–245, 1976.
64.
ShulginA. T., MDMA: Common Questions, Grassroots, pp. 23–26, 1985, reprinted from Pharmchem Newsletter, 14, 1985.
65.
DowlingC. G., Life Magazine, pp. 89–93, August 1985.
66.
Microgram, 18: 9, p. 117, 1985.
67.
HartJ. B., Composition of Illicit Drugs and the Use of Drug Analysis in Abuse Abatement, Journal of Psychedelic Drugs, 5, pp. 83–88, 1972.
68.
Substance Abuse Report, 16: 6, pp. 4–6, Pace Publications, New York, June 1985.
69.
GreerG., MDMA: A New Psychotropic Compound and Its Effects In Humans, unpublished article, 1983.
70.
HardmanH. F.HaavikC. O., and SeeversM. H., Relationship of the Structure of Mescaline and Seven Analogs to Toxicity and Behavior in Five Species of Laboratory Animals, Toxicology and Applied Pharmacology, 25, pp. 299–309, 1973.
71.
NicholsD. E.PfisterW. R., and YimG. K. W., LSD and the Phenylethylamine Hallucinogens: New Structural Analogy and Implications for Receptor Geometry, Life Sciences, 22, pp. 2165–2174, 1978.
72.
NicholsD. E., Structure-Activity Relationship of Phenylethylamine Hallucinogens, Journal of Pharmacology Science, 70, pp. 839–849, 1981.
73.
ShaferJ., Designer Drugs, Science News, pp. 65–67, March 1985.
74.
NicholsD. E. and KostubaL., Steric Effects of Substituents of Phenylethylamine Hallucinogens, Journal of Medical Chemistry, 22, pp. 1264–1266, 1979.
75.
LangstonJ. W.BallardP.TetrudJ. W., and IrwinI., Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis, Science, pp. 979–980, February 25, 1983.
76.
TaylorR. L.MaurerJ. I., and TinklenbergJ. R., Management of Bad Trips in an Evolving Drug Scene, Journal of the American Medical Association, 213, pp. 422–425, 1970.
